Loading...
Projects / Programmes source: ARIS

Medicinal chemistry - drug design, synthesis and evaluation

Periods
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   
1.04.00  Natural sciences and mathematics  Chemistry   

Code Science Field
3.01  Medical and Health Sciences  Basic medicine 
1.04  Natural Sciences  Chemical sciences 
Keywords
Medicinal chemistry, drug discovery, drug development, drug design, organic synthesis, biological evaluation, anti-neurodegeneration drugs, antimicrobial drugs, immunomodulatory drugs, anticancer drugs, toxicology.
Evaluation (rules)
source: COBISS
Points
21,440.75
A''
3,934.62
A'
11,285.3
A1/2
15,624.99
CI10
18,501
CImax
367
h10
60
A1
76.74
A3
19.08
Data for the last 5 years (citations for the last 10 years) on February 22, 2024; A3 for period 2018-2022
Data for ARIS tenders ( 04.04.2019 – Programme tender , archive )
Database Linked records Citations Pure citations Average pure citations
WoS  1,088  23,737  20,358  18.71 
Scopus  1,141  25,859  22,273  19.52 
Researchers (59)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  21456  PhD Marko Anderluh  Pharmacy  Researcher  2022 - 2024  368 
2.  52092  PhD Damjan Avsec  Pharmacy  Junior researcher  2022 - 2024  49 
3.  36454  PhD Maruša Bizjak  Biochemistry and molecular biology  Researcher  2022  30 
4.  34350  PhD Aljoša Bolje  Chemistry  Researcher  2022  45 
5.  37459  PhD Andrej Emanuel Cotman  Chemistry  Researcher  2022 - 2024  54 
6.  19281  PhD Zdenko Časar  Chemistry  Researcher  2022 - 2024  165 
7.  54784  Jaka Dernovšek  Pharmacy  Junior researcher  2022 - 2024  29 
8.  50400  PhD Ana Dolšak  Pharmacy  Researcher  2022  27 
9.  50490  Martina Durcik  Pharmacy  Junior researcher  2022 - 2024  59 
10.  55890  Svit Ferjančič Benetik  Pharmacy  Junior researcher  2022 - 2024 
11.  31879  Petra Ferkov    Technical associate  2022 - 2024 
12.  34841  Maja Frelih  Forestry, wood and paper technology  Technical associate  2022 - 2024  16 
13.  26512  PhD Rok Frlan  Pharmacy  Researcher  2022 - 2024  113 
14.  15706  PhD Tanja Gmeiner  Pharmacy  Researcher  2022  146 
15.  15284  PhD Stanislav Gobec  Pharmacy  Head  2022 - 2024  827 
16.  50814  PhD Katarina Grabrijan  Pharmacy  Researcher  2022 - 2024 
17.  32036  PhD Martina Hrast Rambaher  Pharmacy  Researcher  2022 - 2024  123 
18.  24400  PhD Janez Ilaš  Pharmacy  Researcher  2022 - 2024  244 
19.  56841  Ana Jug  Pharmacy  Junior researcher  2022 - 2024 
20.  18619  PhD Maša Kandušer  Pharmacy  Researcher  2022 - 2024  160 
21.  21459  PhD Nataša Karas Kuželički  Pharmacy  Researcher  2022 - 2024  171 
22.  56840  Vid Kavaš  Pharmacy  Junior researcher  2022 - 2024 
23.  01463  PhD Danijel Kikelj  Pharmacy  Retired researcher  2022 - 2024  565 
24.  21692  Irena Klančnik Mavec    Technical associate  2022 - 2024 
25.  36438  PhD Damijan Knez  Pharmacy  Researcher  2022 - 2024  194 
26.  26495  PhD Nina Kočevar Glavač  Pharmacy  Researcher  2022 - 2024  236 
27.  55892  Anja Kodila  Pharmacy  Junior researcher  2022 - 2024 
28.  30815  PhD Meta Kokalj Ladan  Pharmacy  Researcher  2022 - 2024  33 
29.  55572  PhD Alen Krajnc  Pharmacy  Researcher  2022 - 2024  31 
30.  36423  PhD Eva Kranjc  Pharmacy  Researcher  2022  30 
31.  34223  PhD Tijana Markovič  Pharmacy  Researcher  2022 - 2024  58 
32.  53584  PhD Anže Meden  Pharmacy  Researcher  2022 - 2024  40 
33.  12443  PhD Irena Mlinarič Raščan  Pharmacy  Researcher  2022 - 2024  529 
34.  23419  PhD Janez Mravljak  Pharmacy  Researcher  2022 - 2024  201 
35.  50623  PhD Doroteja Novak  Pharmacy  Researcher  2022 - 2024  19 
36.  19061  PhD Aleš Obreza  Pharmacy  Researcher  2022 - 2024  329 
37.  28861  PhD Stane Pajk  Pharmacy  Researcher  2022 - 2024  188 
38.  37648  Katja Perc    Technical associate  2022 - 2024  11 
39.  19317  PhD Lucija Peterlin Mašič  Pharmacy  Researcher  2022 - 2024  405 
40.  55894  Martina Piga  Pharmacy  Junior researcher  2022 - 2024 
41.  52376  PhD Matic Proj  Pharmacy  Junior researcher  2022 - 2024  63 
42.  55895  Edvin Purić  Pharmacy  Junior researcher  2022 - 2024 
43.  29603  PhD Matjaž Ravnikar  Pharmacy  Researcher  2022 - 2024  70 
44.  08519  PhD Marija Sollner Dolenc  Pharmacy  Researcher  2022 - 2024  651 
45.  30816  PhD Izidor Sosič  Pharmacy  Researcher  2022 - 2024  247 
46.  25490  PhD Matej Sova  Pharmacy  Researcher  2022 - 2024  163 
47.  53583  PhD Maša Sterle  Pharmacy  Junior researcher  2022 - 2024  16 
48.  52378  Nika Strašek Benedik  Pharmacy  Junior researcher  2022 - 2024  24 
49.  29982  PhD Alenka Šmid  Pharmacy  Researcher  2022 - 2024  122 
50.  52094  Andrej Šterman  Pharmacy  Junior researcher  2022  14 
51.  33335  PhD Eva Tavčar  Pharmacy  Researcher  2022 - 2024  78 
52.  35325  Martina Tekavec    Technical associate  2022 - 2024 
53.  28334  PhD Tihomir Tomašić  Pharmacy  Researcher  2022 - 2024  368 
54.  52375  PhD Žan Toplak  Pharmacy  Researcher  2022 - 2024  24 
55.  34512  PhD Dunja Urbančič  Pharmacy  Researcher  2022 - 2024  56 
56.  50503  PhD Matjaž Weiss  Pharmacy  Technical associate  2022  33 
57.  17438  Damijana Zalar    Technical associate  2022 - 2024 
58.  18633  PhD Anamarija Zega  Pharmacy  Researcher  2022 - 2024  185 
59.  28905  PhD Nace Zidar  Pharmacy  Researcher  2022 - 2024  215 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,522 
Abstract
The long-term goal of the research programme is the discovery of new bioactive small molecules with a potential for development into drugs for use in important therapeutic areas through combined medicinal chemistry approaches. In the next period, the research programme will focus on the discovery and rational design, synthesis and biological evaluation of molecules with the ability of modulating validated drug targets. This process will produce new anti-neurodegenerative, antimicrobial, immunomodulatory and anticancer agents of high importance for public health. The research programme will address a variety of drug targets involved in transmembrane and intracellular signalling, i.e. bacterial and human enzymes, membrane, intracellular and nuclear receptors and ion channels. Contemporary medicinal chemistry strategies, including biomimetic and natural products-inspired design, fragment-based drug design (FBDD), approaches for achieving selectivity and drug-like properties will be applied. Ligands capable of modulating two or more drug targets of interest at the same time (MTDLs) will also be designed. The major proposed research topics for the next research programme period include development of new drugs targeting (i) neurodegeneration through inhibition of cholinesterases, monoamine oxidases and kinases, and modulation of monoaminergic receptors and oxidative targets, (ii) multidrug resistant bacteria and coronaviruses through inhibition of DNA gyrase, topoisomerase IV, MurA, D-Ala-D-Ala ligase B, penicillin biding proteins, proteasome, enoyl acyl carrier protein reductase (InhA) and cysteine proteases, (iii) the immune system through modulation of Toll-like receptors and galectins, inhibition of immunoproteasome and O-linked ß-N-acetylglucosamine transferase (OGT), (iv) cancer through inhibition of the human ether-a-go-go channels (hERG), potassium voltage-gated channels (Kv1.3), heat shock protein 90 (Hsp90), DNA topoisomerase II?, proteasome and modulation of the prostaglandin E2 receptor 4 (EP4). Toxicological aspects of the drug discovery process including the determination of (i) PADMET properties of new compounds, (ii) the mechanism of toxicity of endocrine disrupting chemicals, (iii) the influence of metabolism on biological activity and toxicity, and (iv) the effects of antioxidants on oxidative stability of compounds will also be a major research topic in this research programme.
Significance for science
The importance of the proposed research programme for the development of science lies in (i) the discovery of novel bioactive compounds that have the potential to be developed into drugs for important therapeutic areas and (ii) the development of methods for their design, synthesis and insight into their mechanism of action at the molecular level. The outcome of the research programme will be innovative new molecules that act as modulators of important validated drug targets in antineurodegenerative, antimicrobial, immunomodulatory and anticancer therapeutic areas. The PADMET properties of these new compounds and the impact of their metabolism on biological activity and toxicity will also be determined. The knowledge gained from this proposed research programme will be of high scientific value and will be directly applicable in the preclinical drug discovery process. The treatment strategies presented in this research programme for neurodegenerative diseases such as Alzheimer's and Parkinson's disease, infectious diseases caused by resistant bacteria and coronaviruses, immunodeficiency diseases, and cancer have been neglected, but may lead to promising new lead compounds and potential drugs. The information obtained in this proposed research programme on the occurrence and adverse effects of some chemicals on human health will also be a very important contribution to the development of guidelines, policies and regulations for harmonized assessment and risk management at national and European level. This will make an important contribution to the science platform for the protection of public health.
Significance for the country
The Slovenian pharmaceutical industry is currently one of the most important industries in the Slovenian economy. Despite its current generic character, the Slovenian pharmaceutical industry is research-oriented and needs creative and competent scientists. Young scientists trained in the proposed research programme will gain competences for autonomous creative work in the pharmaceutical industry, where they will set novel research priorities. They will be perfectly trained for research work in pharmaceutical industry, universities, other research institutes and government agencies. During the last funding period, members of the programme group supervised twenty-two completed scientific PhDs, all of whom successfully found employment: 12 of them in the pharmaceutical industry, eight in universities and public research institutions, and two abroad. This is an important socio-economic achievement of the research program to date and is a guarantee of prosperity for future PhD students. The proposed research programme will generate novel bioactive compounds with high potential for development into lead compounds and drugs. They can be an excellent starting point for the development of innovative drugs in collaboration with the Slovenian and international pharmaceutical industry. The results related to the development of alternative synthetic routes for drug synthesis, protected by several patent applications, find their direct application in the Slovenian generic pharmaceutical industry. Some of the results of the research programme have reached a high level of technological maturity, which will enable creation of spin-off companies. The promotion of scientific excellence, which is one of the main objectives of the proposed research program, will contribute to the validation of Slovenian science through publications in leading scientific journals and participation in the most important international scientific conferences worldwide. A broad network of international collaborations, which are an important attribute of the proposed research programme, is a good way to promote Slovenian science and build strategic alliances for the benefit of Slovenian and global science. All these activities will contribute to the creation and preservation of the country's national identity in Europe and in the world. The social development of Slovenia and the growth of its scientific culture is an important goal of the proposed research programme. Therefore, communication of the programme activities to various target groups is mandatory. All researchers involved in the programme will promote the programme and ensure that their research results are presented to the public in a way that can be understood by all. This will improve public understanding of drug discovery processes, cancer, multi-drug resistant bacterial infections, neurodegenerative diseases and immune system diseases. It will also raise awareness of the challenges to which the proposed programme is responding and contribute to the popularization of science among young people and in society.
Views history
Favourite